Kenvue Inc

Kenvue Inc(KVUE)股票分析

$19.570

-0.305 (-1.56%)收盘时

Loading chart…
最高
19.840
开盘
19.770
成交量加权均价
19.60
成交量
11.09M
市值
35.27B
最低
19.383
成交额
217.42M
企业价值/息税折旧摊销前利润(TTM)
12.42

Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).

AI 分析 of Kenvue Inc (KVUE)

买入

Kenvue Inc is a good buy right now due to its current price of $19.57, which is close to the average analyst price target of $19. Additionally, the stock has shown a strong year-to-date change of +12.99% and a 1-year change of +29.77%. The RSI is at 71.33, indicating that the stock is in a strong momentum phase, although it is approaching overbought territory. The main risk is the forward P/E ratio of 14.73, which suggests that the stock may be overvalued if earnings do not meet expectations.

分析师评级(1)

-3.63% 下跌空间
卖出
0 买入
0 持有
1 卖出
当前: 19.57
最低
17.00
平均
18.86
最高
23.00

UBS

2026-08-11

目标价

$19

中性

Barclays

2026-07-21

目标价

$19

Equal Weight

UBS

2026-07-16

目标价

$20

中性

Citi

2026-04-15

目标价

$19

中性

Barclays

2026-04-14

目标价

$18

Equal Weight

估值指标

Kenvue Inc(KVUE)当前预期市盈率为 14.73,5 年平均预期市盈率为 17.50。

预期市盈率

低估
5 年均值 P/E
17.50
当前P/E
14.73
高估
19.71
低估
15.30

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
12.65
当前EV/EBITDA
12.42
高估
13.79
低估
11.50

预期市销率

合理
5 年均值 P/S
2.48
当前P/S
2.39
高估
2.80
低估
2.15

Alphio AI 对 KVUE 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%KVUE

$25.34

情景价格

基

基准

基准 · 50%KVUE

$22.26

情景价格

悲

悲观

悲观 · 25%KVUE

$19.40

情景价格

持有 KVUE 的大户

Y

Yacktman Asset Management LP

+ 持有KVUE

+7.18%

3个月收益率

T

Trajan Wealth, L.L.C.

+ 持有KVUE

+5.82%

3个月收益率

M

Magnetar Capital Partners, LP

+ 持有KVUE

+4.93%

3个月收益率

S

Saturna Capital Corporation

+ 持有KVUE

+4.41%

3个月收益率

C

Capstone Investment Advisors, LLC

+ 持有KVUE

+4.33%

3个月收益率

S

Skye Global Management LP

+ 持有KVUE

+4.12%

3个月收益率

KVUE 常见问题 —— 由 Alphio AI 解答

Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM). It operates in the Consumer Non-Cyclicals sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

Kenvue Inc is a good buy right now due to its current price of $19.57, which is close to the average analyst price target of $19. Additionally, the stock has shown a strong year-to-date change of +12.99% and a 1-year change of +29.77%. The RSI is at 71.33, indicating that the stock is in a strong momentum phase, although it is approaching overbought territory. The main risk is the forward P/E ratio of 14.73, which suggests that the stock may be overvalued if earnings do not meet expectations.

1 analysts cover KVUE: 0 rate it Buy, 0 Hold and 1 Sell. The average price target is 18.86.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易